Prostate cancer Immune profiling before, during and after HDR-brachytherapy in local relapsed prostate cancer.

Recruiting

• Conditions: Expression of PD-(L)-1; prostate cancer; 10036958

• Registration Number: NL-OMON48348
• Lead Sponsor: MAASTRO clinic

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 15 April 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 10

Inclusion Criteria

- Local relapse of prostate cancer, who is candidate for a salvage HDR
treatment.
- 18 years or older
- Willing and able to comply with the study prescriptions.
- Before patient registration, written informed consent must be given according
to ICH/GCP, and national/local regulations.

Exclusion Criteria

- Not eligible for proposed (HDR brachytherapy) treatment.
- No compliance

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Primary endpoint: expression of PD-(L)-1 in the tumor.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Secondary endpoints: presence of CXCL12, IL-23 receptor in the tumor at 4<br /><br>different time points (before and after the 1st fraction; before the 2nd and<br /><br>3rd fraction of the salvage treatment). Furthermore, increase of T cell<br /><br>infiltration, and HLA class I-A,B,C expressive lymphocytes will be detected.</p><br>